Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellard R, Kenyon M, Hutt D, Aerts E, de Ruijter M, Chabannon C, et al. The EBMT immune effector cell nursing guidelines on CAR-T therapy: a framework for patient care and managing common toxicities. Clin Hematol Int. 2022;4:75–88.

Article  PubMed  PubMed Central  Google Scholar 

Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.

Article  CAS  PubMed  Google Scholar 

Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019;94:E209–13.

Article  PubMed  PubMed Central  Google Scholar 

Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978–88.

Article  CAS  PubMed  Google Scholar 

Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106:2417–26.

Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790–800.

Article  CAS  PubMed  Google Scholar 

Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Ther Adv Hematol. 2022;13:20406207221087511.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131:1094–105.

Article  CAS  PubMed  Google Scholar 

Horvei P, Sakemura R, Cox MJ, Ruff MW, Hefazi M, Tapper EE, et al. Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro. Blood. 2019;134:2859.

Article  Google Scholar 

Oliai C, de Vos S. Case report: sustained remission achieved from anti-CD19 CAR T cell therapy despite prior treatment with anti-CD19 antibody tafasitamab (MOR208) in a patient with relapsed and refractory diffuse large B-cell lymphoma. Blood. 2019;134:5360.

Article  Google Scholar 

Sakemura RL, Manriquez-Roman C, Horvei P, Cox MJ, Huynh T, Girsch JH, et al. CD19 antigen occupancy on cancer cells with the CD19 monoclonal antibody tafasitamab improves the activation, antitumor efficacy, and safety profile of CART19 cell therapy. Blood. 2022;140:2362–4.

Article  Google Scholar 

Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4:3850–2.

Article  PubMed  PubMed Central  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.

Article  CAS  PubMed  Google Scholar 

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294–308.

Article  CAS  PubMed  Google Scholar 

Qualls D, Buege MJ, Dao P, Caimi PF, Rutherford SC, Wehmeyer G, et al. Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): real world outcomes in a multicenter retrospective study. Blood. 2022;140:787–9.

Article  Google Scholar 

Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, et al. The AntiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy. Clin Lymphoma Myeloma Leuk. 2022;22:e335–9.

Article  CAS  PubMed  Google Scholar 

Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, et al. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40:187–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021;138:1081–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica. 2018;103:e215–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155–65.

Article  CAS  PubMed  Google Scholar 

Gouni S, Rosenthal AC, Crombie JL, Ip A, Kamdar MK, Hess B, et al. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022;6:2757–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023;108:98–109.

Article  CAS  PubMed  Google Scholar 

Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220–31.

Article  CAS  PubMed  Google Scholar 

Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9:e327–39.

Article  CAS  PubMed  Google Scholar 

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023;41:2238–47.

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41:2238–47.

Article  CAS  PubMed  Google Scholar 

Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, et al. Barriers to enrollment in clinical trials of patients with aggressive B-Cell NHL that progressed after CAR T-cell therapy. Blood Adv. 2023;7:1572–6.